Taich Adam 4
4 · 10x Genomics, Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
10x Genomics CFO Adam Taich Receives 106,579 RSUs
What Happened
- Adam Taich, Chief Financial Officer of 10x Genomics (TXG), was granted 106,579 restricted stock units (RSUs) on February 26, 2026. The grant is reported as an acquisition at $0.00 (no cash paid at grant). This is a compensation award, not an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (filed within the standard two-business-day window).
- Transaction type/code: A — Grant/Award (RSUs).
- Shares granted: 106,579 RSUs; reported price: $0.00; total reported cash value at acquisition: $0.
- Vesting: Each RSU converts to one share upon vesting. 1/12th of the RSUs vest on each quarterly anniversary beginning February 21, 2026 (i.e., quarterly over 12 quarters, subject to continued service).
- Shares owned after transaction: Not specified in the provided Form 4 excerpt.
Context
- These RSUs are a common form of executive compensation and are contingent on continued service; they do not represent an immediate sale or purchase of shares. The award will translate into actual shares only as the RSUs vest over time.
Insider Transaction Report
Form 4
Taich Adam
Chief Financial Officer
Transactions
- Award
Class A Common Stock
[F1]2026-02-26+106,579→ 394,996 total
Footnotes (1)
- [F1]Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/12th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.
Signature
/s/ Randy Wu, as Attorney-in-Fact for Adam Taich|2026-03-02